Clinical Trials Logo

Solid Tumor clinical trials

View clinical trials related to Solid Tumor.

Filter by:

NCT ID: NCT03057145 Completed - Solid Tumor Clinical Trials

Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors

Start date: March 10, 2017
Phase: Phase 1
Study type: Interventional

This research study is studying a combination of targeted therapies as a possible treatment for Advanced Solid Tumors. The study interventions involved in this study are: - LY2606368 - Olaparib

NCT ID: NCT03053466 Completed - Solid Tumor Clinical Trials

APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors

Start date: March 27, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and recommended dose schedule of APL-501 in individuals with advanced or relapsed or recurrent solid tumors.

NCT ID: NCT03051477 Completed - Solid Tumor Clinical Trials

Trial of Mistletoe Extract in Patients With Advanced Solid Tumors

Start date: March 1, 2017
Phase: Phase 1
Study type: Interventional

This study will seek to determine the safety and toxicity profile as well as the maximum tolerated dose of Helixor® M in patients with advanced solid tumors.

NCT ID: NCT03042910 Completed - Solid Tumor Clinical Trials

A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors

Start date: October 13, 2016
Phase: Phase 1
Study type: Interventional

This study is designed to evaluate the effects of talazoparib on cardiac repolarization in patients with advanced solid tumors with no available standard treatment options.

NCT ID: NCT03027284 Completed - Solid Tumor Clinical Trials

A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer

Start date: February 3, 2017
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate tolerability of merestinib monotherapy or in combination with other anti-cancer agents in Japanese participants with advanced and/or metastatic cancer.

NCT ID: NCT03027128 Completed - Solid Tumor Clinical Trials

QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors

Start date: August 2, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether haNK™ for Infusion is safe and effective in the treatment of metastatic or locally advanced solid tumors.

NCT ID: NCT03015324 Completed - Solid Tumor Clinical Trials

Biological Effects of Agent on PAR-4 Levels With Resected Solid Tumors

Start date: August 8, 2017
Phase: Phase 1
Study type: Interventional

Hydroxychloroquine will be administered on an outpatient basis within 12 weeks after primary surgery followed by adjuvant chemotherapy /or radiation therapy (if needed). Hydroxychloroquine will be administered orally at a dose of 400 mg daily for 90 days. Subjects will receive HCQ every day.

NCT ID: NCT03013491 Completed - Lymphoma Clinical Trials

PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

Start date: January 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered intravenously (IV) as a single agent or in combination with ipilimumab or vemurafenib in adult subjects with advanced or recurrent solid tumors or lymphomas. PROCLAIM-CX-072: PRObody CLinical Assessment In Man CX-072 clinical trial CX-072 is a Probody™ therapeutic directed against PD-L1 (programmed cell death ligand 1). Probody therapeutics are proteolytically-activatable antibodies (Abs) designed to widen the therapeutic index by minimizing drug interaction with normal tissue while retaining anti-tumor activity. Probody therapeutics are "masked" to attenuate binding to target in healthy tissue but can become "unmasked" in the tumor microenvironment by tumor-specific protease activity. PROBODY is a trademark of CytomX Therapeutics, Inc.

NCT ID: NCT03009292 Completed - Solid Tumor Clinical Trials

Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor

Start date: August 6, 2018
Phase: Phase 1
Study type: Interventional

Study E7080-C086-108 is an open-label, single- and multiple-dose pharmacokinetic (PK) study of lenvatinib (administered orally, once a day [QD]) in Chinese participants with solid tumor. A total of 12 participants will be enrolled to evaluate the PK of 24 milligrams (mg) QD dosing of lenvatinib.

NCT ID: NCT02987166 Completed - Solid Tumor Clinical Trials

HDCRT Plus Pembrolizumab in Advanced Malignancies

UVA-AM-001
Start date: March 21, 2017
Phase: Phase 1
Study type: Interventional

This study is a pilot study to evaluate high-dose conformal radiation therapy (HDCRT) administered in combination with pembrolizumab in patients with solid tumors.